ArticleJournal of atherosclerosis and thrombosis2022
Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apoe
Article in Journal of atherosclerosis and thrombosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Nanomedicine in Cardiovascular Inflammation: Novel Diagnostic and Therapeutic Strategies.Journal of personalized medicine · 2026Review
- The Blockade of Delta-Like Ligand 1 Inhibits Atherosclerotic Lesion Formation and Attenuates Plaque Vulnerability.Journal of atherosclerosis and thrombosis · 2026Article
- Macrophage Gsα promotes NLRP3 stability and its intervention attenuates abdominal aortic aneurysm in male mice.Nature communications · 2026Article
- Review
- Multifunctional nanoparticles in abdominal aortic aneurysm management: from basic research to clinical transformation.Journal of nanobiotechnology · 2025Review
- Recent Advances in Nanomedicine-Mediated Abdominal Aortic Aneurysm Treatment.Small methods · 2025Review
- Multifunctional PLGA nanosystems: enabling integrated diagnostic and therapeutic strategies.Frontiers in pharmacology · 2025Review
- Regulatory effects of statins on CCL2/CCR2 axis in cardiovascular diseases: new insight into pleiotropic effects of statins.Journal of inflammation (London, England) · 2024Article
- Diagnostic value of uric acid to high-density lipoprotein cholesterol ratio in abdominal aortic aneurysms.Annals of medicine · 2024Article
- Novel Applications in Controlled Drug Delivery Systems by Integrating Osmotic Pumps and Magnetic Nanoparticles.Sensors (Basel, Switzerland) · 2024Review
- Integrating Natural Deep Eutectic Solvents into Nanostructured Lipid Carriers: An Industrial Look.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Multiscale physics-basedFrontiers in drug delivery · 2024Review
- Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities.International journal of molecular sciences · 2023Review
- Tissue Engineering and Targeted Drug Delivery in Cardiovascular Disease: The Role of Polymer Nanocarrier for Statin Therapy.Biomedicines · 2023Review
- The future for the therapeutics of abdominal aortic aneurysm: engineered nanoparticles drug delivery for abdominal aortic aneurysm.Frontiers in bioengineering and biotechnology · 2023Review
- Single-cell transcriptomeFrontiers in cardiovascular medicine · 2022Article
- No Effect of Hypercholesterolemia on Elastase-Induced Experimental Abdominal Aortic Aneurysm Progression.Biomolecules · 2021Article
- Targeting the Extracellular Matrix in Abdominal Aortic Aneurysms Using Molecular Imaging Insights.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimAbdominal aortic aneurysm (AAA) is a lethal and multifactorial disease. To prevent a rupture and dissection of enlarged AAA, prophylactic surgery and stenting are currently available. There are, however, no medical therapies preventing these complications of AAA. Statin is one of the candidates, but its efficacy on AAA formation/progression remains controversial. We have previously demonstrated that nanoparticles (NPs) incorporating pitavastatin (Pitava-NPs)-clinical trials using these nanoparticles have been already conducted-suppressed progression of atherosclerosis in apolipoprotein E-deficient ( Apoe
methodsAngiotensin II was intraperitoneally injected by osmotic mini-pumps to induce AAA formation in Apoe
resultsIntravenously administered Pitava-NPs (containing 0.012 mg/kg/week pitavastatin) inhibited AAA formation accompanied with reduction of macrophage accumulation and monocyte chemoattractant protein-1 (MCP-1) expression. Ex vivo molecular imaging revealed that Pitava-NPs not only reduced macrophage accumulation but also attenuated matrix metalloproteinase activity in the abdominal aorta, which was underpinned by attenuated elastin degradation.
conclusionThese results suggest that Pitava-NPs inhibit AAA formation associated with reduced macrophage accumulation and MCP-1 expression. This clinically feasible nanomedicine could be an innovative therapeutic strategy that prevents devastating complications of AAA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.